Editorial
Dear Friends,
We begin this edition of our newsletter with an invitation to a new webinar course! Together with ESNM, we have prepared an exciting series of seven webinars, which will provide a full picture of the C. difficile infection (CDI), from the importance of a healthy gut microbiota to detecting CDI and testing methods, to current and future therapeutic approaches.
Next up, Vassilios Fanos, Full Professor of Pediatrics at the University of Cagliari (Italy), met with the GMFH team and elaborated on the factors that influence the first 1,000 days of a newborn’s life and the role of Bifidobacterium species in gut microbiota development and immune training, as well as the clinical evidence for supplementing with Bifidobacterium species in early life.
You will also come across a new article that looks at the risk factors for developing C. difficile-associated disease, the spectrum of manifestations and the impact of the COVID-19 pandemic on the occurrence of C. difficile infection.
Finally, scientists at the European Molecular Biology Laboratory and Cambridge University elucidate how common drugs accumulate in gut bacteria and potentially reduce the effectiveness of medication.
Happy reading!
The GMFH publishing team
|
